<DOC>
	<DOCNO>NCT02329717</DOCNO>
	<brief_summary>This study evaluate efficacy safety PBI-05204 , extract leave Nerium oleander , patient Stage IV metastatic pancreatic cancer . All patient receive PBI-05204 .</brief_summary>
	<brief_title>Efficacy Safety Study PBI-05204 Patients With Stage IV Metastatic Pancreatic Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>1 . Patient male female age ≥18 year . 2 . Patient histologicallyconfirmed Stage IV malignant metastatic adenocarcinoma pancreas ; ( ) relapse refractory standard therapy therapy exists would curative might provide significant benefit ( b ) intolerant refuse standard chemotherapy , therefore , experimental therapy reasonable option . 3 . Patient measurable disease , determine Investigator use RECIST , version 1.1 , determine within 28 day baseline ( C1D1 ) . 4 . Patient ECOG performance status 0 ( fully active , able carry predisease activity without restriction ) 1 ( unable perform physically strenuous activity ambulatory able carry work light sedentary nature ) , assess C1D1 , first dose PBI 05204 . 5 . Patient predict lifeexpectancy ≥3 month . 6 . Patient adequate bone marrow function define : Absolute neutrophil count ( ANC ) ( neutrophil band ) ≥1.5 x 10 ^9/L Platelet count ≥100 x10^9/L Hemoglobin ≥9.0 g/dL 7 . Patient adequate hepatic function define : Total bilirubin within normal limit ( WNL ) institution , unless bilirubin abnormality consider due Gilbert 's syndrome . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤2.0 x institutional upper limit normal ( ULN ) , , patient know liver metastasis , ≤5.0 x institutional ULN . Serum albumin ≥3.0 g/dL . 8 . Patient adequate renal function define : Serum creatinine ≤1.5 institutional ULN 9 . Patient serum potassium magnesium level WNL institution total serum calcium ionized calcium level ≥ low limit normal ( LLN ) . Patients low potassium , calcium , and/or magnesium level may receive supplementation meet protocol entry criterion . ( Calcium supplementation prohibit start PBI05204 ; see Appendix 2 . ) 10 . Patient provide sign date informed consent prior initiation study procedure . 11 . Patient his/her partner agree use adequate contraception provide write informed consent 3 month last dose PBI 05204 , follow : For woman : Negative pregnancy test screening ( Day 3 Day 1 ) C1D1 compliant medicallyapproved contraceptive regimen 3 month treatment period document surgically sterile ( hysterectomy , bilateral tubal ligation bilateral oophorectomy ) postmenopausal ( define amenorrhea ≥12 consecutive month ; receive hormone replacement therapy [ HRT ] document serum follicle stimulate hormone [ FSH ] level &gt; 35 mIU/mL ) . For men : Compliant medicallyapproved contraceptive regimen 3 month treatment period document surgically sterile . Men whose sexual partner childbearing potential must agree use medicallyapproved contraceptive regimen study 3 month treatment period . 12 . Patient capable swallow study drug capsule whole . 13 . Patient willing able participate study comply study requirement . 1 . Patient uncontrolled significant cardiovascular disease , include : Myocardial infarction within 6 month C1D1 . Uncontrolled angina within 3 month C1D1 . Congestive heart failure , define New York Heart Association ( NYHA ) Class II , within 3 month C1D1 ( see Appendix 1 ) . Diagnosed suspected congenital long QT syndrome . Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , WolffParkinsonWhite [ WPW ] syndrome , torsade de pointes ) , prolong QTc interval preentry ECG ( &gt; 450 msec ) . If automate reading prolong ( i.e. , &gt; 450 msec ) , ECG manually overread . Any history second thirddegree heart block . ( Patients pacemaker may eligible . ) Heart rate &lt; 50 bpm screening . Uncontrolled hypertension ( blood pressure &gt; 160 mmHg systolic &gt; 100 mmHg diastolic ) . 2 . Patient require use concomitant medication contraindicate cardiac glycoside and/or know prolong QT/QTc interval study participation ( see Appendix 2 ) . 3 . Patient evidence uncontrolled malabsorptive diarrhea would prevent adequate absorption PBI 05204 . 4 . Patient dementia alter mental status would prohibit understanding rendering informed consent . 5 . Patient uncontrolled severe intercurrent medical condition ( include uncontrolled brain metastasis ) . Patients stable brain metastasis either treat treat stable dose steroids/anticonvulsants allow provide dose change within 4 week first dose PBI 05204 , anticipate dose change study participation . 6 . Patient underwent major surgery within 4 week first dose PBI 05204 receive cancerdirected therapy ( chemotherapy , radiotherapy , hormonal therapy , biologic immunotherapy , etc . ) investigational drug device within 4 week ( 6 week mitomycin C , nitrosoureas , liposomal doxorubicin ) 5 halflives agent ( whichever short ) first dose PBI 05204 . ( For agent total 5 halflives &lt; 10 day , must minimum 10 day termination investigational drug administration PBI 05204 ) . Note prior liverdirected therapy permit ( i.e. , chemoembolization , radioembolization ) , long target lesion liver demonstrate growth liverdirected treatment . Any drugrelated toxicity , exception alopecia , recover ≤ Grade 1 . 7 . If female , patient pregnant breastfeeding . 8 . Patient evidence serious active infection ( e.g. , infection require treatment intravenous antibiotic ) . 9 . Patient known human immunodeficiency virus ( HIV ) hepatitis B C infection , patient may increase risk toxicity due concomitant treatment , diseaserelated symptom may preclude accurate assessment safety PBI 05204 . 10 . Patient important medical illness abnormal laboratory finding , Investigator 's opinion , would increase risk participate study . 11 . Patient history malignancy treat curative intent within previous 5 year exception adequately treat nonmelanoma skin cancer carcinoma situ cervix . Patients previous invasive cancer eligible treatment complete 5 year prior initiate current study treatment , evidence recurrent disease . 12 . Patient previously expose PBI 05204 . 13 . Patient history allergic reaction attribute compound similar chemical biologic composition PBI05204 ( i.e. , cardiac glycoside compound ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>